Zogenix — Corporate Update (January 2012)
26 slides from Zogenix's corporate update, Jan 9, 2012
Slide 1: Zogenix Update
Exhibit 99.1 ® ZOGENIX UPDATE January 2012 NASDAQ: ZGNX
Slide 2: Forward Looking Statements
Forward Looking Statements Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward- looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assumin
Slide 3: Commercializing and Developing Products for Treatment of CNS Disorders and Pain
Commercializing and Developing Products for Treatment of Central Nervous System (CNS) Disorders and Pain GROWING SALES PREPARING NDA IND STUDIES IN 2012 st Needle-Free, stOral, Single-Entity st Once-Monthly, 1 Commercial Product Acute Migraines and 1 Hydrocodone, 12-Hour Extended Release for 1 Needl
Slide 4: Goals Completed Since IPO
Goals Completed Since IPO Zohydro Building on Track Record of Successful Execution Completed Enrollment of Phase 3 Efficacy Study 801 Announced Positive Phase 3 Efficacy Top–Line Results for Study 801 Last Patient Completion for Safety SUMAVEL DosePro Study 802 Pre-NDA Meeting with FDA in Continued
Slide 5: Single Use, Needle-Free, Commercial Product Marketed for Acute Migraine and Cluster Headaches
st Single Use, Needle-Free, 1 Commercial Product Marketed for Treating Acute Migraine and Cluster Headaches 5
Slide 6: 30 Million People in the U.S. Suffer Migraines
30 Million People in the U.S. Suffer Migraines** 75% of Patients Symptoms and Nature of Episodes Vary Widely Are Women Disabling Headache Pain, 4-72 Hours in Duration The 9th Leading Cause of Disability $25 B Annual Estimated Cost to Employers in Women Globally 63% Suffer 1 Attack per Month 7th Most
Slide 7: SUMAVEL DosePro: A Differentiated Migraine Therapy
SUMAVEL DosePro: A Differentiated Migraine Therapy FAST EFFECTIVE Pain Relief in as little as Pain Relief minutes Pain Free 98% of Patients Correctly Used SUMAVEL DosePro During Migraine Attacks on Their First Try at Home COMPLETE EASY TO USE Sources: SUMAVEL DosePro Prescribing Information 7
Slide 8: Growing Prescriptions Since Launch
Growing Prescriptions Since Launch $8.8M January 2010 – November 2011 $8.7M Net Sales* Net Sales ~100,000 Total Prescriptions** 38% Refill Rate (3Q 2011) $7.5M $6.8M Net Sales 7,109 Net Sales 6,822 Refill Prescriptions $5.7M 4,910 New Prescriptions Net Sales 4,487 $4.2M Net Sales 2,907 1,674 $1.9M 1
Slide 9: Amended SUMAVEL DosePro Co-Promotion Agreement
Amended SUMAVEL DosePro Co-Promotion Agreement Astellas agreement will end March 31, 2012 Beginning 2Q 2012, Zogenix will assume full responsibility for the continued commercialization of the brand – Evaluating potential co-promotion partners who could complement the Zogenix sales force efforts – De
Slide 10: SUMAVEL DosePro Growth Drivers
SUMAVEL DosePro Growth Drivers Sales Force Expansion 95 reps calling on neurologists, pain specialists and high Rx PCPs beginning in 4Q 2011 Evaluating new co-promotion opportunities to supplement Zogenix U.S. sales team Migraine Toolbox Launch Helps patients choose most appropriate therapy Supports
Slide 11: Choosing the Right Tools for Specific Migraine Attacks
Choosing the Right Tools for Specific Migraine Attacks SUMAVEL DosePro MigraineTOOLBOX A comprehensive new patient starter kit with relevant product information for physician, patient and pharmacist, including a free sample, $15 co-pay card, carrying case, training material, support resources, video
Slide 12: SUMAVEL DosePro Phase IV Study: Improves Treatment Satisfaction and Patient Confidence
SUMAVEL DosePro Phase IV Study: Improves Treatment Satisfaction and Patient Confidence* Improvement in Overall Treatment Pain Relief % Satisfaction versus oral triptans (p=0.0007) Pain Free % Substantial Improvement in Confidence to treat repeated attacks after using SUMAVEL DosePro (65% confident/v
Slide 13: Oral, Single-Entity Extended Release Hydrocodone for Treating Chronic Pain
st Oral, Single-Entity 1 (without acetaminophen), Extended Release Hydrocodone for Treating Chronic Pain 13
Slide 14: Zohydro product profile
Effective 12-hour pain relief without acetaminophen Oral, extended-release, single- 1st entity hydrocodone (hydrocodone bitartrate) Consistent 12-hour pain relief Improved convenience and Single-Entity Hydrocodone, compliance Multiple Strengths (10-50 mg) Uses Alkermes’ Proprietary SODAS Delivery Sy
Slide 15: Zohydro in the Marketplace
Zohydro in the Marketplace Large market characterized by dose escalation and opioid rotation Hydrocodone isthe only opioid not currently available in ERform and available only in combination with APAP/NSAID; FDA advisory committee noted single entity formulation of hydrocodone would be logical subst
Slide 16: Pivotal Phase 3 Efficacy Study (Study 801) Met Endpoints
Pivotal Phase 3 Efficacy Study (Study 801) Met Endpoints Significant difference in chronic pain relief (lower back) vs. placebo (p=0.008) based on average mean changes in daily pain intensity (Numeric Rating Scale) Key secondary endpoints support Zohydro efficacy – Significantly higher proportion of
Slide 17: Summary of Safety (Study 801)
Zohydro Phase 3 Trial Summary of Safety (Study 801) Safe and generally well tolerated – Adverse event profile consistent with approved oral, extended release opioid products Overall % of subjects experienced an AE – C/T Phase = 33.7% – Treatment Phase = 28.8% Most Commonly reported Adverse Events (
Slide 18: Zohydro NDA Submission Expected Early 2Q 2012
Zohydro NDA Submission Expected Early 2Q 2012 More than 1,000 Patients with Chronic Pain Treated with Zohydro Phase 3 open label safety study (Study 802) completed; fulfills database requirements for 505(b)(2) NDA – 300 patients completed six months of exposure – 100 patients completed 12 months of
Slide 19: Zohydro Key Commercial Events and Goals
Zohydro Key Commercial Events and Goals Physician Advisory Boards 2011 Branding and Market Research Payer/Pricing Research APAP data dissemination 2012 Develop Marketing Communications and Launch Campaign Expand Zogenix Sales Team from 95 Reps to ~ 250 Reps to Support Zohydro 2013 Launch and SUMAVEL
Slide 20: Relday (risperidone)
Relday TM (risperidone) DosePro Needle-Free Delivery System st Once-monthly risperidone 1 available as a needle-free subcutaneous injection for treatment of schizophrenia 20
Slide 21: Relday Needle-Free SubQ Injection for Schizophrenia
Relday Needle-Free SubQ Injection for Schizophrenia Proprietary long-acting injection formulation of risperidone (Durect’s SABER technology) deliverable by DosePro 2H 2011 Potential Benefits IND Enabling Studies – Consistent, sustained drug release over one month per injection – High drug loading fa
Slide 22: Relday Addresses Treatment Needs
Relday Addresses Treatment Needs Long-acting injections reduces the risk of noncompliance compared with oral treatments Growing US and EU market for long-acting injectable products - exceeded $1.5 billion in 2010 (according to industry reports) – Risperdal Consta, 100 mg/month >$1000 Highly concentr
Slide 23: DosePro Technology Platform
DosePro Technology: New CNS Applications and Out Licensing Opportunities DosePro Technology Platform Validated Delivery Option for Additional Medications, Including Biologics and Small Molecules Second Generation Internal Development Technology Technology Out Licensing Injectable CNS Drug (1mL devic
Slide 24: Large Commercial Opportunities
Large Commercial Opportunities 12.2 Million TRxper Year 128 Million TRx per Year 48% of Episodes Upon Morning Wakening (between 4 -9 am) 128M TRx Hydrocodone only Patient/ Market (~30% for Chronic Use) 29% of Sufferers Reported Vomiting as a Symptom of Migraine Attacks Segments 30% of Patients Fail
Slide 25: Financial Summary
Financial Summary P&L ($ Millions) Financial Highlights ($ Millions) 9 months ended September 30, 2011 Revenue $ 29.8 Market Capitalization ~$184m (January 6, 2012) Operating Expense $ 85.5 Cash Balance $ 56.5m At 12/31/11 (unaudited) Debt Loss From Operations $ 55.8 At 12/31/11 $30M Royalty Financi
Slide 26: Planned Goals
Planned Goals Building on Track Record of Zohydro Successful Execution NDA Submission – early Q2 2012 Publish Pivotal Data Explore partnership Commercial Readiness Expand Sales Force Upon Approval SUMAVEL DosePro Relday Continue U.S. Script Growth Q1 2012 transition of Astellas File IND in 1H 2012 s